Is metronomic chemotherapy less toxic than conventional chemotherapy in the randomized phase 2 XeNa trial combining navelbine oral and Xeloda for HER2 negative breast cancer patients?

A. S. Brems-Eskildsen; S Linnet; Adam Andrzej Luczak; H. A.  Nielsen; P. M. Vestlev; B. B. Jensen; T. Hilling; T. Dongsgaard; C. B. Jensen; J. Neimann; A. B. Nygaard; S. T. Langkjer

doi:10.1007/s00520-015-2712-y

Is metronomic chemotherapy less toxic than conventional chemotherapy in the randomized phase 2 XeNa trial combining navelbine oral and Xeloda for HER2 negative breast cancer patients?

A. S. Brems-Eskildsen, S Linnet, Adam Andrzej Luczak, H. A. Nielsen, P. M. Vestlev, B. B. Jensen, T. Hilling, T. Dongsgaard, C. B. Jensen, J. Neimann, A. B. Nygaard, S. T. Langkjer

Research output: Contribution to journal › Conference abstract in journal › Research › peer-review

9 Citations (Scopus)

Original language	English
Article number	26-017-P
Journal	Supportive Care in Cancer
Volume	23
Issue number	Suppl 1
Pages (from-to)	S353
ISSN	0941-4355
DOIs	https://doi.org/10.1007/s00520-015-2712-y
Publication status	Published - 2015
Event	MASCC/ISOO 2015 Annual Meeting: Supportive Care in Cancer - København, Denmark Duration: 25 Jun 2015 → 27 Jun 2015

Conference

Conference	MASCC/ISOO 2015 Annual Meeting
Country/Territory	Denmark
City	København
Period	25/06/2015 → 27/06/2015

Access to Document

10.1007/s00520-015-2712-y

AUB Link

Search for the material in Aalborg University Library's search engine

Cite this

Brems-Eskildsen, A. S., Linnet, S., Luczak, A. A., Nielsen, H. A., Vestlev, P. M., Jensen, B. B., Hilling, T., Dongsgaard, T., Jensen, C. B., Neimann, J., Nygaard, A. B., & Langkjer, S. T. (2015). Is metronomic chemotherapy less toxic than conventional chemotherapy in the randomized phase 2 XeNa trial combining navelbine oral and Xeloda for HER2 negative breast cancer patients? Supportive Care in Cancer, 23(Suppl 1), S353. Article 26-017-P. https://doi.org/10.1007/s00520-015-2712-y

@article{1a76ba3351544718bb0f51a118918ae5,

title = "Is metronomic chemotherapy less toxic than conventional chemotherapy in the randomized phase 2 XeNa trial combining navelbine oral and Xeloda for HER2 negative breast cancer patients?",

author = "Brems-Eskildsen, {A. S.} and S Linnet and Luczak, {Adam Andrzej} and Nielsen, {H. A.} and Vestlev, {P. M.} and Jensen, {B. B.} and T. Hilling and T. Dongsgaard and Jensen, {C. B.} and J. Neimann and Nygaard, {A. B.} and Langkjer, {S. T.}",

year = "2015",

doi = "10.1007/s00520-015-2712-y",

language = "English",

volume = "23",

pages = "S353",

journal = "Supportive Care in Cancer",

issn = "0941-4355",

publisher = "Physica-Verlag",

number = "Suppl 1",

note = "MASCC/ISOO 2015 Annual Meeting ; Conference date: 25-06-2015 Through 27-06-2015",

}

Brems-Eskildsen, AS, Linnet, S, Luczak, AA, Nielsen, HA, Vestlev, PM, Jensen, BB, Hilling, T, Dongsgaard, T, Jensen, CB, Neimann, J, Nygaard, AB & Langkjer, ST 2015, 'Is metronomic chemotherapy less toxic than conventional chemotherapy in the randomized phase 2 XeNa trial combining navelbine oral and Xeloda for HER2 negative breast cancer patients?', Supportive Care in Cancer, vol. 23, no. Suppl 1, 26-017-P, pp. S353. https://doi.org/10.1007/s00520-015-2712-y

Is metronomic chemotherapy less toxic than conventional chemotherapy in the randomized phase 2 XeNa trial combining navelbine oral and Xeloda for HER2 negative breast cancer patients? / Brems-Eskildsen, A. S.; Linnet, S; Luczak, Adam Andrzej et al.
In: Supportive Care in Cancer, Vol. 23, No. Suppl 1, 26-017-P, 2015, p. S353.

Research output: Contribution to journal › Conference abstract in journal › Research › peer-review